GENE ONLINE|News &
Opinion
Blog

2018-03-13| Asia-Pacific

Bainbridge Investments Bids for Healthcare Industry and Advanced Technology in Taiwan

by GeneOnline
Share To

By Joanne Shih

Nick Chini, Chairman and CEO of Bainbridge Investments, a US direct private equity investments company, stated that Bainbridge is optimistic about investing in Taiwan’s healthcare and entertainment industries and plans to participate in bidding for the Gate of Taipei, a skyscraper development in Taipei, in combination with advanced technologies such as artificial intelligence (AI) and augmented reality (AR). In addition, the strong foundation in medical system and healthcare in Taiwan also attracts Bainbridge to deploy Taiwan’s healthcare market.

Nick said that Bainbridge has evaluated the market in Taiwan for many years and decided to set up three major projects in Taiwan, including bidding for the Gate of Taipei real estate investment, entering healthcare industry, and setting up an AI Forum in Taiwan.

Nick asid, “We not only see the Gate of Taipei real estate investment, but also are optimistic about Taiwan’s high-tech and biotechnology industries.” Therefore, the company plans to invest in the healthcare industry in Taiwan intending to merge the technologies in healthcare and medical care with commercial real estate, leisure facilities, restaurants, department stores, or studios to build a giant hospitality development.

Bainbridge Investments has a professional advisory group for all phases of planning, design and construction, and has extensive experience with projects in the United States, Abu Dhabi and China. Considering the Gate of Taipei as not only a national development but also an important hub for Southeast Asia and Asia, Nick has faith in this investment will bring in more opportunities, and will target on the top 500 companies in the world once they take the bid.

Reference
http://bainbridgeinvestments.com
http://www.chinatimes.com/newspapers/20180312000177-260202

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
35% of Americans May Avoid Seeking Care Due to Concerns Over Healthcare Prices
2022-10-31
Thermo Fisher Announces $59 Million Lab Expansion In Kentucky, Reveals AI Deal With Genoox
2022-10-28
Transforming Southern California Biotech Landscape: An Interview With SoCalBio CEO Ahmed Enany
2022-10-18
LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!